Blackrock, INC Schedule 13G passive stakes

BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a 1.6% beneficial ownership stake in Destination XL Group Inc. as of June 30, 2025.

BlackRock, Inc. has reported a 7.1% beneficial ownership stake in D-Wave Quantum Inc., holding 22,170,378 shares of common stock as of June 30, 2025, for investment purposes.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 6.8% beneficial ownership stake in EQT Corporation, representing 40,723,549 shares as of June 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 5.5% beneficial ownership stake in Edgewise Therapeutics Inc., totaling 5,824,866 common shares.

BlackRock, Inc. has filed a Schedule 13G, reporting a 5.4% beneficial ownership stake in Eledon Pharmaceuticals, Inc. as of June 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 0.6% of Elevation Oncology, Inc.'s common stock as of June 30, 2025.

BlackRock, Inc. has reported a 7.3% beneficial ownership stake in Emergent BioSolutions Inc., holding 3,977,535 shares of common stock as of June 30, 2025, for passive investment purposes.

BlackRock, Inc. has filed an amended Schedule 13G, reporting beneficial ownership of 13.1% of Energizer Holdings Inc.'s common stock as of June 30, 2025.

BlackRock, Inc. has filed an Amendment No. 3 to Schedule 13G, reporting a 14.5% beneficial ownership stake in Enpro Inc.'s common stock as of June 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 4.8% passive beneficial ownership stake in ESSA Bancorp, Inc. as of June 30, 2025.

BlackRock, Inc. has reported a 5.7% beneficial ownership stake in Eton Pharmaceuticals, Inc., holding 1,530,357 shares of common stock as of June 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a reduced beneficial ownership stake of 2.3% in Everspin Technologies Inc. common stock.

BlackRock, Inc. has filed an Amendment No. 3 to its Schedule 13G, disclosing a 4.3% beneficial ownership stake in Exact Sciences Corp. common stock as of June 30, 2025.

BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a 4.9% beneficial ownership stake in FRP Holdings Inc. as of June 30, 2025.

BlackRock, Inc. has filed a Schedule 13G, reporting a passive beneficial ownership of 5.3% of the common stock of Forge Global Holdings, Inc.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 16.5% beneficial ownership stake in Four Corners Property Trust Inc. as of June 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 1.7% passive beneficial ownership stake in Generation Bio Co., though the filing contains conflicting information regarding a subsidiary's ownership and an unusual future event date.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 3.0% beneficial ownership in GrowGeneration Corp's common stock.

BlackRock, Inc. has reported a 6.5% beneficial ownership stake in Cipher Mining Inc., holding over 21 million shares of common stock.

BlackRock, Inc. has filed an Amendment No. 6 to its Schedule 13G, reporting a passive beneficial ownership of 8.2% of Compass Minerals International Inc.'s common stock as of June 30, 2025.

BlackRock, Inc. has filed an Amendment No. 6 to its Schedule 13G, disclosing a 6.6% beneficial ownership stake in Nabors Industries Ltd., totaling 1,040,834 common shares.

BlackRock, Inc. has filed a Schedule 13G, reporting a 5.0% beneficial ownership stake in Barrick Gold Corp's common stock as of June 30, 2025.

BlackRock, Inc. has filed an Amendment No. 2 to Schedule 13G, reporting a 4.8% beneficial ownership stake in IMAX Corp as of June 30, 2025.

BlackRock, Inc. has reported a 5.1% beneficial ownership stake in Lionsgate Studios Corp. common stock, totaling 14,498,606 shares, as of June 30, 2025.

BlackRock, Inc. files Schedule 13G, disclosing beneficial ownership of 6.2% of Xenon Pharmaceuticals Inc.'s common stock as of June 30, 2025.

BlackRock, Inc. has reported a 5.1% beneficial ownership stake in Bank of Montreal's common stock as of June 30, 2025.

BlackRock, Inc. has filed a Schedule 13G, reporting a 5.0% beneficial ownership stake in Magna International Inc. as of June 30, 2025.

BlackRock, Inc. has reported a 5.0% beneficial ownership stake in The Royal Bank of Canada's common stock, holding over 70 million shares as of June 30, 2025.

BlackRock, Inc. has filed a Schedule 13G, reporting a passive beneficial ownership of 6.9% of the common stock of CRISPR Therapeutics AG as of June 30, 2025.

BlackRock, Inc. has reported beneficial ownership of 5.8% of Constellium SE's Common Stock, totaling 8,274,063 shares, as of June 30, 2025.